Maria Schäfers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maria Schäfers has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Claudia Sommer
Department of Neurology, University Hospital Würzburg, Würzburg, Germany
2 shared publications - Andreas Kribben
Department of Nephrology, University Hospital Essen, Essen, Germany
1 shared publication - Anna Dzagnidze
Department of Neurology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany
1 shared publication - Bernd Liedert
Department of Neurology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany
1 shared publication C. Geis
1 shared publication- Dietrich Büsselberg
Weill Cornell Medicine-Qatar, Education City, Qatar Foundation
1 shared publication
Latest Publications
- 10 November 2013
- Published by Springer Nature in Der Nervenarzt
- Vol. 84 (12) , 1445-1450
Aktuelle Therapie neuropathischer Schmerzen
- 10 November 2013
- Published by Springer Nature in Der Nervenarzt
- Vol. 84 (12) , 1445-1450
Aktuelle Therapie neuropathischer Schmerzen
- 11 December 2012
- Published by Wiley in European journal of pain
- Vol. 17 (6) , 881-892
Analgesic ineffectiveness of lacosamide after spinal nerve ligation and its sodium channel activity in injured neurons
Background Lacosamide is a novel anti‐epileptic drug that enhances the slow‐ and not fast‐inactivating state of voltage‐gated sodium channels. Lacosamide has demonstrated analgesic efficacy in several animal studies but preclinical studies on neuropathic pain models are rare, and recent clinical trials showed no superior analgesic effects. Methods Here, we examine whether an acute or chronic administration of lacosamide (3–60 mg/kg, i.p.) attenuates pain behaviour induced by spinal nerve ligation (SNL). To validate the inhibitory efficacy of lacosamide on voltage‐gated sodium channels, sodium currents in naïve and SNL‐injured dorsal root ganglion (DRG) neurons were recorded using whole‐cell patch clamping. Results Lacosamide only marginally attenuated thermal hyperalgesia, but not tactile allodynia when applied once 7 or 14 days after SNL and showed no analgesic effect when applied daily for 19 days. In naïve neurons, 100 μmol/L lacosamide inhibited sodium channel currents by 58% and enhanced the slow inactivation (87% for lacosamide vs. 47% for control). In contrast, lacosamide inhibited sodium currents in injured DRG neurons by only 15%, while the effects on slow inactivation were diminished. Isolated currents from the NaV1.8 channel subtype were only marginally changed by lacosamide. Conclusion The reduced effectiveness of lacosamide on voltage‐gated sodium channel currents in injured DRG neurons may contribute to the reduced analgesic effect observed for the SNL model.
- 11 December 2012
- Published by Wiley in European journal of pain
- Vol. 17 (6) , 881-892
Analgesic ineffectiveness of lacosamide after spinal nerve ligation and its sodium channel activity in injured neurons
Background Lacosamide is a novel anti‐epileptic drug that enhances the slow‐ and not fast‐inactivating state of voltage‐gated sodium channels. Lacosamide has demonstrated analgesic efficacy in several animal studies but preclinical studies on neuropathic pain models are rare, and recent clinical trials showed no superior analgesic effects. Methods Here, we examine whether an acute or chronic administration of lacosamide (3–60 mg/kg, i.p.) attenuates pain behaviour induced by spinal nerve ligation (SNL). To validate the inhibitory efficacy of lacosamide on voltage‐gated sodium channels, sodium currents in naïve and SNL‐injured dorsal root ganglion (DRG) neurons were recorded using whole‐cell patch clamping. Results Lacosamide only marginally attenuated thermal hyperalgesia, but not tactile allodynia when applied once 7 or 14 days after SNL and showed no analgesic effect when applied daily for 19 days. In naïve neurons, 100 μmol/L lacosamide inhibited sodium channel currents by 58% and enhanced the slow inactivation (87% for lacosamide vs. 47% for control). In contrast, lacosamide inhibited sodium currents in injured DRG neurons by only 15%, while the effects on slow inactivation were diminished. Isolated currents from the NaV1.8 channel subtype were only marginally changed by lacosamide. Conclusion The reduced effectiveness of lacosamide on voltage‐gated sodium channel currents in injured DRG neurons may contribute to the reduced analgesic effect observed for the SNL model.
- Open Access
- 15 July 2009
- Published by Springer Nature in BMC Neuroscience
- Vol. 10 (1) , 77
Erythropoietin overrides the triggering effect of DNA platination products in a mouse model of Cisplatin-induced neuropathy
Cisplatin mediates its antineoplastic activity by formation of distinct DNA intrastrand cross links. The clinical efficacy and desirable dose escalations of cisplatin are restricted by the accumulation of DNA lesions in dorsal root ganglion (DRG) cells leading to sensory polyneuropathy (PNP). We investigated in a mouse model by which mechanism recombinant erythropoietin (rhEPO) protects the peripheral nervous system from structural and functional damage caused by cisplatin treatment with special emphasis on DNA damage burden.A cumulative dose of 16 mg cisplatin/kg resulted in clear electrophysiological signs of neuropathy, which were significantly attenuated by concomitant erythropoietin (cisplatin 32,48 m/s +/- 1,68 m/s; cisplatin + rhEPO 49,66 m/s +/- 1,26 m/s; control 55,01 m/s +/- 1,88 m/s; p < 0,001). The co-application of rhEPO, however, did not alter the level of unrepaired cisplatin-DNA lesions accumulating in DRG target cells. Micro-morphological analyses of the sciatic nerve from cisplatin-exposed mice showed damaged myelin sheaths and mitochondria. Co-administered rhEPO inhibited myelin sheaths from structural injuries and resulted in an increased number of intact mitochondria.The protective effect of recombinant erythropoietin is not mediated by reducing the burden of DNA platination in the target cells, but it is likely to be due to a higher resistance of the target cells to the adverse effect of DNA damage. The increased frequency of intact mitochondria might also contribute to this protective role.
- 15 July 2009
- Published by Springer Nature in BMC Neuroscience
- Vol. 10 (1) , 77
Open AccessErythropoietin overrides the triggering effect of DNA platination products in a mouse model of Cisplatin-induced neuropathy
Cisplatin mediates its antineoplastic activity by formation of distinct DNA intrastrand cross links. The clinical efficacy and desirable dose escalations of cisplatin are restricted by the accumulation of DNA lesions in dorsal root ganglion (DRG) cells leading to sensory polyneuropathy (PNP). We investigated in a mouse model by which mechanism recombinant erythropoietin (rhEPO) protects the peripheral nervous system from structural and functional damage caused by cisplatin treatment with special emphasis on DNA damage burden.A cumulative dose of 16 mg cisplatin/kg resulted in clear electrophysiological signs of neuropathy, which were significantly attenuated by concomitant erythropoietin (cisplatin 32,48 m/s +/- 1,68 m/s; cisplatin + rhEPO 49,66 m/s +/- 1,26 m/s; control 55,01 m/s +/- 1,88 m/s; p < 0,001). The co-application of rhEPO, however, did not alter the level of unrepaired cisplatin-DNA lesions accumulating in DRG target cells. Micro-morphological analyses of the sciatic nerve from cisplatin-exposed mice showed damaged myelin sheaths and mitochondria. Co-administered rhEPO inhibited myelin sheaths from structural injuries and resulted in an increased number of intact mitochondria.The protective effect of recombinant erythropoietin is not mediated by reducing the burden of DNA platination in the target cells, but it is likely to be due to a higher resistance of the target cells to the adverse effect of DNA damage. The increased frequency of intact mitochondria might also contribute to this protective role.
- 1 November 2008
- Published by Elsevier in Neuroscience
- Vol. 157 (2) , 414-423
Selective stimulation of either tumor necrosis factor receptor differentially induces pain behavior in vivo and ectopic activity in sensory neurons in vitro
- 1 November 2008
- Published by Elsevier in Neuroscience
- Vol. 157 (2) , 414-423
Selective stimulation of either tumor necrosis factor receptor differentially induces pain behavior in vivo and ectopic activity in sensory neurons in vitro
- 1 June 2008
- Published by Elsevier in Neuroscience Letters
- Vol. 437 (3) , 188-193
Effect of cytokines on neuronal excitability
- 1 June 2008
- Published by Elsevier in Neuroscience Letters
- Vol. 437 (3) , 188-193
Effect of cytokines on neuronal excitability
- 1 November 2007
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 7 (11) , 1613-1627
Anticytokine therapy in neuropathic pain management
Cytokine activation or dysregulation is implied in a variety of painful disease states. Numerous experimental studies provide evidence that proinflammatory cytokines induce or facilitate neuropathic pain. Cytokine levels are rapidly and markedly upregulated in the peripheral nerves, dorsal root ganglia, spinal cord and in particular regions of the brain, after peripheral nerve injuries. Direct receptor-mediated actions on afferent nerve fibers as well as cytokine effects involving further mediators have been reported. Whereas direct application of exogenous proinflammatory cytokines induces pain, blockade of these cytokines or application of anti-inflammatory cytokines reduces pain behavior in most experimental paradigms. Cytokine measurements may identify patients at risk of developing chronic pain associated with their neuropathic conditions, as in the examples of peripheral neuropathies and postherpetic neuralgia. Anticytokine agents currently on the market are effective for the treatment of mostly inflammatory pain conditions, and are starting to be introduced for neuropathic pain states; however, their use is limited by potential life-threatening complications. Owing to the pleiotropy and redundancy of the cytokine system, the successful approach may not be inhibition of one particular cytokine but strategies shifting the balance between pro- and anti-inflammatory cytokines in properly selected patients. Agents that specifically target downstream signaling molecules may provide hope for safer and more specific therapies.
- 1 November 2007
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 7 (11) , 1613-1627
Anticytokine therapy in neuropathic pain management
Cytokine activation or dysregulation is implied in a variety of painful disease states. Numerous experimental studies provide evidence that proinflammatory cytokines induce or facilitate neuropathic pain. Cytokine levels are rapidly and markedly upregulated in the peripheral nerves, dorsal root ganglia, spinal cord and in particular regions of the brain, after peripheral nerve injuries. Direct receptor-mediated actions on afferent nerve fibers as well as cytokine effects involving further mediators have been reported. Whereas direct application of exogenous proinflammatory cytokines induces pain, blockade of these cytokines or application of anti-inflammatory cytokines reduces pain behavior in most experimental paradigms. Cytokine measurements may identify patients at risk of developing chronic pain associated with their neuropathic conditions, as in the examples of peripheral neuropathies and postherpetic neuralgia. Anticytokine agents currently on the market are effective for the treatment of mostly inflammatory pain conditions, and are starting to be introduced for neuropathic pain states; however, their use is limited by potential life-threatening complications. Owing to the pleiotropy and redundancy of the cytokine system, the successful approach may not be inhibition of one particular cytokine but strategies shifting the balance between pro- and anti-inflammatory cytokines in properly selected patients. Agents that specifically target downstream signaling molecules may provide hope for safer and more specific therapies.